A Bayesian Dose-Finding Design Adapting to Efficacy and Tolerability Response
S. Krishna Padmanabhan(Pfizer (United States)), Michael Krams(Wellcome Centre for Human Neuroimaging), Scott Berry(Queen's University), Vladimir Dragalin(Pfizer (United States))
Cited by 8
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818